These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35074757)

  • 1. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma.
    Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L
    Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
    Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
    J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
    [No Abstract]   [Full Text] [Related]  

  • 7. The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations.
    Feng Y; Zhao M; Wang L; Li L; Lei JH; Zhou J; Chen J; Wu Y; Miao K; Deng CX
    Cell Death Dis; 2024 Jan; 15(1):34. PubMed ID: 38212325
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Matsumori T; Kodama Y; Takai A; Shiokawa M; Nishikawa Y; Matsumoto T; Takeda H; Marui S; Okada H; Hirano T; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Marusawa H; Kageyama R; Chiba T; Seno H
    Cancer Res; 2020 Dec; 80(23):5305-5316. PubMed ID: 33067264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
    Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
    J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
    Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
    J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Xu RC; Wang F; Sun JL; Abuduwaili W; Zhang GC; Liu ZY; Liu TT; Dong L; Shen XZ; Zhu JM
    J Transl Med; 2022 Dec; 20(1):579. PubMed ID: 36494846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
    Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
    Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway.
    Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L
    Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.
    Wang J; Zhang K; Wang J; Wu X; Liu X; Li B; Zhu Y; Yu Y; Cheng Q; Hu Z; Guo C; Hu S; Mu B; Tsai CH; Li J; Smith L; Yang L; Liu Q; Chu P; Chang V; Zhang B; Wu M; Jiang X; Yen Y
    Oncotarget; 2015 Aug; 6(22):18905-20. PubMed ID: 26056085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review).
    Yang R; Song Y; Shakoor K; Yi W; Peng C; Liu S
    Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35302174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Profile of Intrahepatic Cholangiocarcinoma.
    Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
    Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
    Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma.
    Chen S; Xie Y; Cai Y; Hu H; He M; Liu L; Liao C; Wang Y; Wang J; Ren X; Zeng Q; Peng H; Shen S; Li S; Li D; Lai J; Peng B; Ren J; Kuang M; Peng S
    Clin Cancer Res; 2022 May; 28(9):1896-1910. PubMed ID: 34526363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
    Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
    Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.